ERBB2 and hepatocellular carcinoma: The combination of luteolin with other clinical drugs, such as sorafenib in hepatocellular carcinoma (HCC) and lapatinib in HER-2+ breast cancer cells, highlights the therapeutic relevance of this approach [33].